# US 2017/0363627 A1 · Reagent kit used for detecting lipoprotein-associated phospholipase a2, and preparation method and application for reagent kit

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0363627 A1
- Document ID: US20170363627A1
- Status: Published application
- Kind: A1
- Application number: 15/543,817
- Filed: 2015-02-10
- Published: 2017-12-21
- Earliest claimed: 2015-02-10
- Assignees: Shenzhen New Industries Biomedical Engineering Co., Ltd.
- Applicants: Shenzhen New Industries Biomedical Engineering Co., Ltd.
- Inventors: Wei RAO; Jinyun YUAN; Qin LI; Ke HUANG; Kai LUO; Dongxia LIN; Tinghua LI
- Web page: https://patentgrep.com/patent/US20170363627A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- C12Q 1/44: involving esterase
- C12Y 301/01004: Phospholipase A2 (3.1.1.4)
- G01N 2333/918: Carboxylic ester hydrolases (3.1.1)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

A reagent kit used for detecting lipoprotein-associated phospholipase A2, and a preparation method for the reagent kit. The reagent kit comprises one or a plurality of first anti-lipoprotein-associated phospholipase A2 antibodies used for binding lipoprotein-associated phospholipase A2 to be measured, and one or a plurality of second anti-lipoprotein-associated phospholipase A2 antibodies marked with a trace marker and binding with the lipoprotein-associated phospholipase A2 to be measured at another site, different from the binding site of the lipoprotein-associated phospholipase A2 to be measured and the first anti-lipoprotein-associated phospholipase A2 antibodies. The reagent kit also comprises a displacing agent, so as to further increase the detection accuracy of the reagent kit. A method using the reagent kit for the detection of lipoprotein-associated phospholipase A2 may take serum as a detection sample, has high repeatability and high accuracy, and measures the concentration of lipoprotein-associated phospholipase A2 in the sample in a highly sensitive manner.

## Claims

### Claim 1

A kit for detecting lipoprotein-associated phospholipase A2, comprising one or more first anti-lipoprotein-associated phospholipase A2 antibodies coated on a magnetic sphere for binding with lipoprotein-associated phospholipase A2 to be detected, and one or more second anti-lipoprotein-associated phospholipase A2 antibodies labeled with a trace marker for binding with the lipoprotein-associated phospholipase A2 to be detected at other binding sites different from the binding sites of the first anti-lipoprotein-associated phospholipase A2 antibodies with the lipoprotein-associated phospholipase A2 to be detected;
wherein the trace marker is at least one selected from the group consisting of luminol and derivatives thereof, isoluminol and derivatives thereof, and acridinium esters; and
wherein the kit further comprises a displacer including water as a solvent and the following components:
at least one selected from the group consisting of 3-[3-(cholamidopropyl) dimethylammonio] propanesulfonate, 8-anilino-1-naphthalenesulfonic acid, sodium deoxycholate, barbiturate, and acetic acid;
newborn bovine serum;
goat serum and/or horse serum;
dithiothreitol;
tris (hydroxymethyl) aminomethane;
hydrated 2-morpholinoethanesulfonic acid;
casein; and
disodium ethylenediaminetetraacetate.

### Claim 2 (depends on 1)

The kit according to claim 1, wherein the first anti-lipoprotein-associated phospholipase A2 antibodies and the second anti-lipoprotein-associated phospholipase A2 antibodies are independently anti-lipoprotein-associated phospholipase A2 monoclonal antibodies and/or anti-lipoprotein-associated phospholipase A2 polyclonal antibodies.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The kit according to claim 2, wherein the trace marker is N-(4-aminobutyl)-N-ethylisoluminol.

### Claim 5 (depends on 2)

The kit according to claim 2, wherein the magnetic sphere is a complex of Fe2O3 or Fe3O4 magnetic particles and an organic polymeric material and has a particle size of 0.1 to 5 microns; and, the magnetic sphere are optionally modified by surface modification to carry one or more active functional groups.

### Claim 6 (depends on 2)

The kit according to claim 2, wherein the first anti-lipoprotein-associated phospholipase A2 antibodies are directly or indirectly coated on the magnetic sphere, and the indirect coating forms include indirect coating via a fluorescein isothiocyanate and anti-fluorescein isothiocyanate antibody system or a streptavidin and biotin system; and
the trace marker directly or indirectly labels the second anti-lipoprotein-associated phospholipase A2 antibodies and the indirect labeling forms include indirect labeling via a fluorescein isothiocyanate and anti-fluorescein isothiocyanate antibody system or a streptavidin and biotin system.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 81)

The kit according to claim 81, wherein the kit comprises the following components in an amount relative to the total amount of the solvent:
at least one selected from the group consisting of 0.1 to 5 wt % of 3-[3-(cholamidopropyl) dimethylammonio] propanesulfonate, 0.1 to 2 wt % of 8-anilino-1-naphthalenesulfonic acid, 0.1 to 2 wt % of sodium deoxycholate, 0.1 to 2 wt % of barbiturate, and 0.1 to 2 vol % of acetic acid;
1 to 50 vol % of newborn bovine serum;
0.1 to 10 vol % of goat serum and/or 0.1 to 10 vol % of horse serum;
0.1 to 10 wt % of dithiothreitol;
0.1 to 10 wt % of tris (hydroxymethyl) aminomethane;
0.1 to 10 wt % of monohydrate 2-morpholinoethanesulfonic acid;
0.01 to 1 wt % of casein; and
0.01 to 1 wt % of disodium ethylenediaminetetraacetate.

### Claim 10 (depends on 9)

The kit of claim 9, wherein the kit further comprises a low-point calibrator and a high-point calibrator of lipoprotein-associated phospholipase A2 and optionally a buffer.

### Claim 11 (depends on 2)

The kit according to claim 2, wherein the concentrations of the first anti-lipoprotein-associated phospholipase A2 antibodies and the second anti-lipoprotein-associated phospholipase A2 antibodies in the kit are each 10 to 200 μg/ml, the concentration of the trace marker is 0.1 to 1 mg/ml, and the concentration of the magnetic sphere is 0.1 to 5 mg/ml.

### Claim 12

A method for preparing a kit for detecting lipoprotein-associated phospholipase A2, comprising:
directly or indirectly coating a first anti-lipoprotein-associated phospholipase A2 antibody on magnetic sphere, and directly or indirectly labeling a second anti-lipoprotein-associated phospholipase A2 antibody with a trace marker, to obtain the kit including one or more first anti-lipoprotein-associated phospholipase A2 antibodies coated on magnetic sphere for binding with lipoprotein-associated phospholipase A2 to be detected, and one or more second anti-lipoprotein-associated phospholipase A2 antibodies labeled with a trace marker for binding with lipoprotein-associated phospholipase A2 to be detected at other binding sites different from the binding sites of the first anti-Lipoprotein-associated phospholipase A2 antibodies with lipoprotein-associated phospholipase A2 to be detected;
wherein the trace marker is at least one selected from the group consisting of luminol and its derivatives, isoluminol and its derivatives, and acridinium esters; and
wherein the method further comprises a step of preparing a displacer as a component of the kit, including: mixing water as a solvent and the following components:
at least one selected from the group consisting of 3-[3-(cholamidopropyl) dimethylammonio] propanesulfonate, 8-anilino-1-naphthalenesulfonic acid, sodium deoxycholate, barbiturate, and acetic acid;
newborn bovine serum;
goat serum and/or horse serum;
dithiothreitol;
tris (hydroxymethyl) aminomethane;
hydrated 2-morpholinoethanesulfonic acid;
casein; and
disodium ethylenediaminetetraacetate.

### Claim 13 (depends on 12)

The method according to claim 12, wherein
the indirect coating includes coating the first anti-lipoprotein-associated phospholipase A2 antibody indirectly via a fluorescein isothiocyanate and anti-fluorescein isothiocyanate antibody system or a streptavidin and biotin system; and
the indirect labeling includes labeling the second anti-lipoprotein-associated phospholipase A2 antibody via a fluorescein isothiocyanate and anti-fluorescein isothiocyanate antibody system or a streptavidin and biotin system.

### Claim 14

(canceled)

### Claim 15 (depends on 12)

A process according to claim 12, wherein the displacer comprises the following components in an amount relative to the total amount of the solvent:
at least one selected from the group consisting of 0.1 to 5 wt % of 3-[3-(cholamidopropyl) dimethylammonio] propanesulfonate, 0.1 to 2 wt % of 8-anilino-1-naphthalenesulfonic acid, 0.1 to 2 wt % of sodium deoxycholate, 0.1 to 2 wt % of barbiturate, and 0.1 to 2 vol % of acetic acid;
1 to 50 vol % of newborn bovine serum;
0.1 to 10 vol % of goat serum and/or 0.1 to 10 vol % of horse serum;
0.1 to 10 wt % of dithiothreitol;
0.1 to 10 wt % of tris (hydroxymethyl) aminomethane;
0.1 to 10 wt % of monohydrate 2-morpholinoethanesulfonic acid;
0.01 to 1 wt % of casein; and
0.01 to 1 wt % of disodium ethylenediaminetetraacetate.

### Claim at position 15

16-17. (canceled)

### Claim 18 (depends on 12)

The method according to claim 12, wherein the trace marker is N-(4-aminobutyl)-N-ethylisoluminol.

### Claim 19 (depends on 12)

The method according to claim 12, wherein the magnetic sphere is a complex of Fe2O3 or Fe3O4 magnetic particles and an organic polymeric material and has a particle size of 0.1 to 5 microns.

### Claim 20 (depends on 12)

The method according to claim 12, wherein, in the kit prepared, the concentrations of the first anti-lipoprotein-associated phospholipase A2 antibodies and the second anti-lipoprotein-associated phospholipase A2 antibodies are each 10 to 200 μg/ml, the concentration of the trace marker is 0.1 to 1 mg/ml, and the concentration of the magnetic sphere is 0.1 to 5 mg/ml.

### Claim 21

A method for detecting lipoprotein-associated phospholipase A2, wherein the method comprises using a kit for detecting lipoprotein-associated phospholipase A2 to detect a concentration of lipoprotein-associated phospholipase A2 in a subject sample by chemiluminescence immunoassay, wherein the kit includes one or more first anti-lipoprotein-associated phospholipase A2 antibodies coated on magnetic sphere for binding with lipoprotein-associated phospholipase A2 to be detected, and one or more second anti-lipoprotein-associated phospholipase A2 antibodies labeled with a trace marker for binding with lipoprotein-associated phospholipase A2 to be detected at other binding sites different from the binding sites of the first anti-Lipoprotein-associated phospholipase A2 antibodies with lipoprotein-associated phospholipase A2 to be detected;
wherein the kit further comprises a displacer including water as a solvent and the following components:
at least one selected from the group consisting of 3-[3-(cholamidopropyl) dimethylammonio] propanesulfonate, 8-anilino-1-naphthalenesulfonic acid, sodium deoxycholate, barbiturate, and acetic acid;
newborn bovine serum;
goat serum and/or horse serum;
dithiothreitol;
tris (hydroxymethyl) aminomethane;
hydrated 2-morpholinoethanesulfonic acid;
casein; and
disodium ethylenediaminetetraacetate.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the trace marker is N-(4-aminobutyl)-N-ethylisoluminol.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the magnetic sphere is a complex of Fe2O3 or Fe3O4 magnetic particles and an organic polymeric material and has a particle size of 0.1 to 5 microns.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the first anti-lipoprotein-associated phospholipase A2 antibody is directly or indirectly coated on the magnetic sphere, and the indirect coating forms include coating the first anti-lipoprotein-associated phospholipase A2 antibody indirectly via a fluorescein isothiocyanate and anti-fluorescein isothiocyanate antibody system or a streptavidin and biotin system; and
the trace marker directly or indirectly labels the second anti-lipoprotein-associated phospholipase A2 antibody, and the indirect labeling forms include labeling the second anti-lipoprotein-associated phospholipase A2 antibody via a fluorescein isothiocyanate and anti-fluorescein isothiocyanate antibody system or a streptavidin and biotin system.

### Claim 25

(canceled)

### Claim 26 (depends on 21)

The method according to claim 21, wherein the kit comprises the following components in an amount relative to the total amount of the solvent:
at least one selected from the group consisting of 0.1 to 5 wt % of 3-[3-(cholamidopropyl) dimethylammonio] propanesulfonate, 0.1 to 2 wt % of 8-anilino-1-naphthalenesulfonic acid, 0.1 to 2 wt % of sodium deoxycholate, 0.1 to 2 wt % of barbiturate, and 0.1 to 2 vol % of acetic acid;
1 to 50 vol % of newborn bovine serum;
0.1 to 10 vol % of goat serum and/or 0.1 to 10 vol % of horse serum;
0.1 to 10 wt % of dithiothreitol;
0.1 to 10 wt % of tris (hydroxymethyl) aminomethane;
0.1 to 10 wt % of monohydrate 2-morpholinoethanesulfonic acid;
0.01 to 1 wt % of casein; and
0.01 to 1 wt % of disodium ethylenediaminetetraacetate.

### Claim 27 (depends on 21)

The method according to claim 21, wherein, in the kit, the concentration of the first anti-lipoprotein-associated phospholipase A2 antibodies and the second anti-lipoprotein-associated phospholipase A2 antibodies are each 10 to 200 μg/ml, the concentration of the trace marker is 0.1 to 1 mg/ml, and the concentration of the magnetic sphere is 0.1 to 5 mg/ml.
